Skip to main content
. 2018 May 7;8:149. doi: 10.3389/fonc.2018.00149

Figure 2.

Figure 2

Strategy for ribonucleotide reductase (RNR) inhibitors in cervical or vaginal cancers. The clinical development strategy for RNR-targeted agents like triapine is to block or to stall DNA repair after a maximum amount of inflicted DNA damage occurs during the G1 or S phases of the cell cycle. This strategy is cytotoxic (1) by itself or (2) disrupts homologous recombination repair.